Published in Blood Weekly, March 23rd, 2006
The phase I, randomized, placebo-controlled, dose-escalation study, the first human trial for any Ebola vaccine, was sponsored by the U.S. National Institute of Allergy and Infectious Diseases (NIAID), U.S. National Institutes of Health (NIH), and conducted at the NIH Clinical Center. The data were presented at the American Society for Microbiology 2006 Biodefense Research meeting in Washington, DC, by...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.